Study Reference No. - C2D01384

Demographic Gender Age Location Compensation
History of allergy to ragweed for at least the last 2 years Males and Females At least 18 years Mississauga, ON $2,800
Study Details

Study Purpose

The primary purpose of this study is to find out if the Test product, Reproxalap Ophthalmic Solution (0.25%), is safe and effective to treat allergic conjunctivitis in comparison to the Vehicle Ophthalmic Solution, when study participants are exposed to airborne ragweed pollen in the Environmental Exposure Chamber (EEC).

Study Duration

Approximately 4 visits that includes Medical Screening (Visit 1), Screening in EEC (Visit 2), and 2 Study Treatment in EEC (Visit 3 and 4).

Study Schedule

General Screening


Medical Screening

Starting 11-Nov. Multiple dates available. Contact recruitment.

Study Visit(s)

Starting 25-Nov. Multiple cohorts/dates. Contact recruitment.

Follow-Up Visit(s)


Other Notes

Bring Valid Photo ID.

COVID-19 test will be conducted prior to designated visits.